Importance of genetic counseling referrals for high-risk women with endometrial cancer despite intact mismatch repair immunohistochemistry.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 1537-1537
Author(s):  
Jessica Lee ◽  
Allison L Brodsky ◽  
Deanna Gerber ◽  
Julia Fehniger ◽  
Shabnam Asgari ◽  
...  
2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1503-1503
Author(s):  
Jessica Lee ◽  
Lindsay Gubernick ◽  
Jing-Yi Chern ◽  
Deanna Gerber ◽  
Stephanie V. Blank ◽  
...  

1503 Background: Lynch syndrome accounts for the majority of inherited endometrial cancers and the identification of probands presents a unique opportunity to treat and prevent multiple cancers. This is now even more relevant with the potential of novel immunotherapy agents for women with germline mutations. The diagnosis of endometrial cancer (EC) can provide the indication for women with specific risk factors to undergo genetic testing (GT). We sought to evaluate genetic counseling referrals (GCR) and subsequent GT rates. Methods: All women with EC between 2012 and 2015 were identified. Statistical analyses were performed to evaluate risk factors including age, body mass index (BMI), positive family history defined as two or more family members with Lynch-related cancers, and tumor mismatch repair (MMR) protein expression loss. Results: A total of 447 women were diagnosed with EC and of these, 107 (24%) were given GCR by their gynecologic oncologist based on their discretion. Compared to non-GCR, GCR women were significantly younger (median 54 vs 65, p < 0.0001) and had lower BMI (median 28.2 vs 30.8, p= 0.007). Of the 107 GCR women, 71 (66%) underwent GT. Of the 71 GT women, 8 (11%) were found to have a germline mutation in one of the MMR genes. Table 1 lists GCR, GT and positive germline mutations among specific high-risk cohorts. Of these cohorts, 56% under 50 years of age, 28% with family history, and 61% with loss of tumor MMR proteins had GCR. Conclusions: Many young, thin EC women with a family history or a tumor MMR deficiency are not given GCR. Among GCR women, 66% underwent GT, despite there being a high rate of germline mutations among these women. It is imperative that high-risk women receive GCR with subsequent GT to capture the maximum number with Lynch syndrome to screen and prevent additional cancers as well as enable cascade testing in family members. Facilitated pathways may be helpful in increasing GCR, as well as GT in EC women. [Table: see text]


2016 ◽  
Vol 3 (3) ◽  
pp. 193
Author(s):  
Sarah Knerr ◽  
M. Robyn Andersen ◽  
Charles W Drescher ◽  
Robert Resta ◽  
Michelle Hager ◽  
...  

2021 ◽  
Vol 9 (4) ◽  
Author(s):  
Y. Chen ◽  
Sushmita Gordhandas ◽  
Kelsey Musselman ◽  
Zhen Zhou ◽  
Brandon Maddy ◽  
...  

Objectives. Beginning in 2014, the Society of Gynecologic Oncology and the American College of Obstetricians and Gynecologists have recommended universal tumor testing for mismatch repair deficiency in endometrial cancer. Mismatch repair testing can triage patients who may benefit from genetic testing for Lynch syndrome. Many women previously diagnosed with endometrial cancer have not undergone mismatch repair tumor testing. We sought to determine the feasibility of retroactive assessment for mismatch repair deficiency among women with diagnosed with endometrial cancer prior to 2014. Methods. Between 2016 and 2018, we identified 36 patients presenting for gynecologic oncology follow-up visits who were previously diagnosed with endometrial cancer. The endometrial pathology underwent tumor assessment for loss of expression of mismatch repair proteins by immunohistochemistry. Patients with abnormal mismatch repair testing were referred to genetic counseling and, if indicated, for germline genetic testing. Results. Thirty-six patients underwent retroactive tumor immunohistochemistry, yielding 10 (28%) abnormal results, including nine (25%) with loss of one or more mismatch repair proteins and one with inconclusive staining (2.8%). All ten patients with abnormal immunohistochemistry were referred to genetic counseling; 9 (90%) accepted the referral and proceeded with genetic testing. One pathogenic mutation was identified in CHEK2 (11%). Five patients (56%) were found to have a variant of unknown significance. Conclusions. Implementation of universal retroactive tumor testing for mismatch repair deficiency in patients previously diagnosed with endometrial cancer is feasible. With the growing use of new molecular classification protocols for endometrial tumors, identification of mismatch repair deficiency may have significant clinicopathologic implications.


2014 ◽  
Vol 24 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Angie Tong ◽  
Scott Kelly ◽  
Rachel Nusbaum ◽  
Kristi Graves ◽  
Beth N. Peshkin ◽  
...  

2005 ◽  
Vol 14 (6) ◽  
pp. 473-484 ◽  
Author(s):  
Jessica A. Ray ◽  
Lois J. Loescher ◽  
Molly Brewer

2008 ◽  
Vol 12 (1) ◽  
pp. 37-52 ◽  
Author(s):  
Beth N. Peshkin ◽  
Tiffani A. DeMarco ◽  
Kristi D. Graves ◽  
Karen Brown ◽  
Rachel H. Nusbaum ◽  
...  

2008 ◽  
Vol 0 (0) ◽  
pp. 080327164308306 ◽  
Author(s):  
Beth N. Peshkin ◽  
Tiffani A. DeMarco ◽  
Kristi D. Graves ◽  
Karen Brown ◽  
Rachel H. Nusbaum ◽  
...  

Author(s):  
Kelechi Njoku ◽  
Joanna Abiola ◽  
Johanna Russell ◽  
Emma J. Crosbie

2014 ◽  
Vol 135 (2) ◽  
pp. 395-396
Author(s):  
A. Beavis ◽  
S. Cheema ◽  
C. Holschneider ◽  
E. Duffy ◽  
M. Amneus

Sign in / Sign up

Export Citation Format

Share Document